BioCorRx (BICX) Accounts Payables (2010 - 2026)

BioCorRx (BICX) has 17 years of Accounts Payables data on file, last reported at $6.6 million in Q1 2026.

• Quarterly Accounts Payables fell 39.38% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (down 39.38% YoY) and the FY2025 annual result came in at $6.4 million, up 14.13% from the prior year.
• Accounts Payables grew to $6.6 million in Q1 2026 per BICX's latest filing, from $6.4 million in the prior quarter.
• The five-year high for Accounts Payables was $11.8 million in Q2 2025, with the low at $2828.0 in Q3 2025.
• Average Accounts Payables over 5 years is $5.2 million, with a median of $4.6 million recorded in 2023.
• The widest YoY moves for Accounts Payables: up 121.49% in 2025, down 99.95% in 2025.
• BioCorRx's Accounts Payables stood at $3.9 million in 2022, then climbed by 18.97% to $4.6 million in 2023, then rose by 19.91% to $5.6 million in 2024, then rose by 14.13% to $6.4 million in 2025, then increased by 3.49% to $6.6 million in 2026.
• Business Quant data shows BICX's Accounts Payables at $6.6 million in Q1 2026, $6.4 million in Q4 2025, and $2828.0 in Q3 2025.